Lawrence B. Afrin, MD

Articles by Lawrence B. Afrin, MD

Improved Metastatic Uterine Papillary Serous Cancer Outcome With Treatment of Mast Cell Activation Syndrome

ByLawrence B. Afrin, MD,Laura S. Spruill, MD, PhD,Stephen I. Schabel, MD,Jennifer L. Young-Pierce, MD

February 16th 2014

A 71-year-old woman not on hormone replacement therapy presented with uterine bleeding. Dilation and curettage revealed complex hyperplasia with atypia, focal clear-cell features, and endocervicitis. Endometrial intraepithelial carcinoma was suspected.

Latest Updated Articles

Uptake of Nononcology Gene Therapy Remains Slow in Hematology
Published: August 16th 2024 | Updated: August 19th 2024
Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLD
Published: March 18th 2024 | Updated: June 3rd 2024
Rapcabtagene Autoleucel Shows Promise for DLBCL in Updated Phase 2 Data
Published: December 7th 2024 | Updated:
Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell Therapy
Published: December 12th 2022 | Updated:
RPE Cell Therapy Shows Improvements in Early GA With AMD
Published: July 14th 2024 | Updated:
Multi-Characteristic Opsin Gene Therapy for Retinitis Pigmentosa Improves Multiple Measures of Vision
Published: May 18th 2023 | Updated:

Lawrence B. Afrin, MD

Articles by Lawrence B. Afrin, MD

Improved Metastatic Uterine Papillary Serous Cancer Outcome With Treatment of Mast Cell Activation Syndrome

Latest Updated Articles

Trending on CGTlive®

Sanofi’s Neovascular Age-Related Macular Degeneration Gene Therapy SAR402663 Garners FDA Fast Track Designation

Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025

Ultragenyx's Glycogen Storage Disease Gene Therapy DTX401 Continues to Enable Decreases in Reductions in Daily Cornstarch Intake at 96 Weeks

Daniel Galbraith, PhD, on Using Targeted Locus Amplification to Analyze Genetically Modified Cells